Skip to main content

Clinical Genomics Licenses Biomarkers from Garvan Institute

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Clinical Genomics today said that it has licensed rights to certain cancer biomarkers from The Garvan Institute of Medical Research.

The Sydney, Australia-based firm said that it has obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer. Clinical Genomics said that it will evaluate the biomarkers for possible development of diagnostic tests for early detection of colorectal cancer.

"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," Lawrence LaPointe, CEO of Clinical Genomics, said in a statement.

The Garvan Institute, which also is based in Sydney, focuses on genetics research in cancer and metabolic syndromes.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.